Marcel canoy (20 résultats)

Softcover. Etat : Fine. Leichte Kratzer / Abnutzungen / Druckstellen; Leichte Verschmutzung / Farbtonveränderung.

Softcover. Etat : Very good.

Etat : Very Good.

Etat : new.

Etat : New. In English.

Etat : New.

Etat : New. 2022. Hardback. . . . . .

Etat : New.

HRD. Etat : New. New Book. Shipped from UK. Established seller since 2000.

Hardback. Etat : New. This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels - in the context of current issues and future trends, including those related to COVID-19 - and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.…

Hardcover. Etat : Brand New. 1st edition. 307 pages. 9.50x6.25x1.00 inches. In Stock.

Hardcover. Etat : new. Hardcover. This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels in the context of current issues and future trends, including those related to COVID-19 and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Etat : New.

Hardback. Etat : New. New copy - Usually dispatched within 4 working days.

Etat : New. 2022. Hardback. . . . . . Books ship from the US and Ireland.

Buch. Etat : Neu. Neuware.

Hardback. Etat : New. This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels - in the context of current issues and future trends, including those related to COVID-19 - and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law.…

Hardcover. Etat : new. Hardcover. This timely book discusses the application of the EU competition rules to pharmaceuticals, covering the prohibitions on anticompetitive agreements and abuse of dominance, and merger control.The author team comprises academic experts and private practitioners who analyse recent case law at both EU (and UK) and Member State levels in the context of current issues and future trends, including those related to COVID-19 and examine the impact of competition law on the behaviour of the pharmaceutical industry. The book carefully considers the balance between competition and innovation, as well as between competition and regulation. It concludes that competition and regulation are not alternatives, but complementary, and that novel ways of taking into account risk and real innovation through competition assessments have been developed.Integrating an overview of competition law, IP law and pharmaceutical regulation, this book will be an ideal read for scholars and graduate students, as well as private and public practitioners interested in pharmaceutical and European law. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.…

Etat : Gut. Zustand: Gut | Sprache: Niederländisch | Produktart: Bücher | Keine Beschreibung verfügbar.

Etat : Hervorragend. Zustand: Hervorragend | Sprache: Niederländisch | Produktart: Bücher | Keine Beschreibung verfügbar.